Skip to main navigation Skip to search Skip to main content

Closed-loop automated drug infusion regulator: A clinically translatable, closed-loop drug delivery system for personalized drug dosing

  • Louis B. DeRidder
  • , Kyle A. Hare
  • , Aaron Lopes
  • , Josh Jenkins
  • , Nina Fitzgerald
  • , Emmeline MacPherson
  • , Niora Fabian
  • , Josh Morimoto
  • , Jacqueline N. Chu
  • , Ameya R. Kirtane
  • , Wiam Madani
  • , Keiko Ishida
  • , Johannes L.P. Kuosmanen
  • , Naomi Zecharias
  • , Christopher M. Colangelo
  • , Hen Wei Huang
  • , Makaya Chilekwa
  • , Nikhil B. Lal
  • , Shriya S. Srinivasan
  • , Alison M. Hayward
  • Brian M. Wolpin, David Trumper, Troy Quast, Douglas A. Rubinson, Robert Langer, Giovanni Traverso

Research output: Contribution to journal › Article › peer-review

Abstract

Background: Dosing of chemotherapies is often calculated according to the weight and/or height of the patient or equations derived from these, such as body surface area (BSA). Such calculations fail to capture intra- and interindividual pharmacokinetic variation, which can lead to order of magnitude variations in systemic chemotherapy levels and thus under- or overdosing of patients. Methods: We designed and developed a closed-loop drug delivery system that can dynamically adjust its infusion rate to the patient to reach and maintain the drug's target concentration, regardless of a patient's pharmacokinetics (PK). Findings: We demonstrate that closed-loop automated drug infusion regulator (CLAUDIA) can control the concentration of 5-fluorouracil (5-FU) in rabbits according to a range of concentration-time profiles (which could be useful in chronomodulated chemotherapy) and over a range of PK conditions that mimic the PK variability observed clinically. In one set of experiments, BSA-based dosing resulted in a concentration 7 times above the target range, while CLAUDIA keeps the concentration of 5-FU in or near the targeted range. Further, we demonstrate that CLAUDIA is cost effective compared to BSA-based dosing. Conclusions: We anticipate that CLAUDIA could be rapidly translated to the clinic to enable physicians to control the plasma concentration of chemotherapy in their patients. Funding: This work was supported by MIT's Karl van Tassel (1925) Career Development Professorship and Department of Mechanical Engineering and the Bridge Project, a partnership between the Koch Institute for Integrative Cancer Research at MIT and the Dana-Farber/Harvard Cancer Center.

Original languageEnglish (US)
Pages (from-to)780-796.e10
JournalMed
Volume5
Issue number7
DOIs
StatePublished - Jul 12 2024
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2024 Elsevier Inc.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Foundational research
  • cancer
  • chemotherapy
  • closed-loop system
  • drug delivery
  • personalized dosing

Fingerprint

Dive into the research topics of 'Closed-loop automated drug infusion regulator: A clinically translatable, closed-loop drug delivery system for personalized drug dosing'. Together they form a unique fingerprint.

Cite this